Abstract
The hyperphosphorylation of tau is a central mechanism in the pathogenesis of Alzheimer’s disease (AD). Lithium is a potent inhibitor of glycogen synthase kinase-3beta (GSK3β), the most important tau kinase in neurons, and may also affect tau phosphorylation by modifying the expression and/or activity of other kinases, such as protein kinase A (PKA), Akt (PKB), and calcium calmodulin kinase-II (CaMKII). The aim of the present study is to determine the effect of chronic lithium treatment on the protein expression of tau and its major kinases in cortical and hippocampal neurons, at distinct working concentrations. Primary cultures of cortical and hippocampal neurons were treated with sub-therapeutic (0.02 mM and 0.2 mM) and therapeutic (2 mM) concentrations of lithium for 7 days. Protein expression of tau and tau-kinases was determined by immunoblotting. An indirect estimate of GSK3β activity was determined by the GSK3β ratio (rGSKβ). Statistically significant increments in the protein expression of tau and CaMKII were observed both in cortical and hippocampal neurons treated with subtherapeutic doses of lithium. GSK3β activity was increased in cortical, but decreased in hippocampal neurons. Distinct patterns of changes in the expression of the remaining tau tau-kinases were observed: in cortical neurons, lithium treatment was associated with consistent decrements in Akt and PKA, whereas hippocampal neurons displayed increased protein expression of Akt and decreased PKA. Our results suggest that chronic lithium treatment may yield distinct biological effects depending on the concentration range, with regional specificity. We further suggest that hippocampal neurons may be more sensitive to the effect of lithium, presenting with changes in the expression of tau-related proteins at subtherapeutic doses, which may not be mirrored by the effects observed in cortical neurons.
This is a preview of subscription content, log in via an institution to check access.
Data availability
Raw data is available in the supplementary material.
Code availability
Software application or custom code.
References
Avila J, Pérez M, Lucas JJ et al (2004) Assembly in vitro of tau protein and its implications in Alzheimer’s disease. Curr Alzheimer Res 1:97–101
Baker S, Götz J (2016) A local insult of okadaic acid in wild-type mice induces tau phosphorylation and protein aggregation in anatomically distinct brain regions. Acta Neuropathol Commun 4:32. https://doi.org/10.1186/s40478-016-0300-0
Berk M, Cowdery S, Williams L, Malhi GS (2017) Recalibrating the risks and benefits of lithium therapy. Br J Psychiatry 211:1–2. https://doi.org/10.1192/bjp.bp.116.193789
Caccamo A, Oddo S, Tran LX, LaFerla FM (2007) Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170:1669. https://doi.org/10.2353/AJPATH.2007.061178
Cardillo GdeM, De-Paula VdeJR, Ikenaga EH et al (2018) Chronic lithium treatment increases telomere length in parietal cortex and hippocampus of triple-transgenic Alzheimer’s disease mice. J Alzheimers Dis 63:93–101. https://doi.org/10.3233/JAD-170838
Castello J, Ragnauth A, Friedman E, Rebholz H (2017) CK2-an emerging target for neurological and psychiatric disorders. Pharmaceuticals (basel) 10:7. https://doi.org/10.3390/ph10010007
Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96:8745–8750
Chiu C-T, Chuang D-M (2011) Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36:461–476. https://doi.org/10.3969/j.issn.1672-7347.2011.06.001
Cho J-H, Johnson GVW (2003) Glycogen synthase kinase 3β phosphorylates tau at both primed and unprimed sites. J Biol Chem 278:187–193. https://doi.org/10.1074/jbc.M206236200
Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14:399–415. https://doi.org/10.1038/s41582-018-0013-z
Conner JM, Lauterborn JC, Yan Q et al (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 17:2295–2313
De-Paula VDJ, Kerr DS, De Carvalho MPF et al (2015) Long-term lithium treatment increases cPLA2 and iPLA2 activity in cultured cortical and hippocampal neurons. Molecules 20:19878–19885. https://doi.org/10.3390/molecules201119663
De-Paula VJ, dos Santos CCC, Luque MCA et al (2021) Acute and chronic lithium treatment increases Wnt/β-catenin transcripts in cortical and hippocampal tissue at therapeutic concentrations in mice. Metab Brain Dis 36:193–197. https://doi.org/10.1007/s11011-020-00638-8
De-Paula VJ, Gattaz WF, Forlenza OV (2016a) Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar Disord 18:692–695. https://doi.org/10.1111/bdi.12449
De-Paula VJ, Kerr DS, Scola G et al (2016b) Lithium distinctly modulates the secretion of pro- and anti- inflammatory interleukins in co-cultures of neurons and glial cells at therapeutic and sub-therapeutic concentrations. Curr Alzheimer Res 13:848–852
Dell’Osso L, Del Grande C, Gesi C et al (2016) A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr Dis Treat 12:1687–1703. https://doi.org/10.2147/NDT.S106479
Ferretti MT, Bruno MA, Ducatenzeiler A et al (2012) Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer’s disease. Neurobiol Aging 33:1329–1342
Fiorentini A, Rosi MC, Grossi C, et al (2010) Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mice. PLoS One 5.https://doi.org/10.1371/journal.pone.0014382
Forlenza OV, de Paula VJ, MacHado-Vieira R et al (2012) Does lithium prevent Alzheimer’s disease? Drugs Aging 29:335–342. https://doi.org/10.2165/11599180-000000000-00000
Forlenza OV, Diniz BS, Radanovic M et al (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351–356. https://doi.org/10.1192/bjp.bp.110.080044
Forlenza OV, Radanovic M, Talib LL, Gattaz WF (2019) Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry 215:668–674. https://doi.org/10.1192/bjp.2019.76
Gattaz WF, Forlenza OV, Talib LL et al (2004) Platelet phospholipase A(2) activity in Alzheimer’s disease and mild cognitive impairment. J Neural Transm 111:591–601. https://doi.org/10.1007/s00702-004-0142-y
Grabrucker A, Vaida B, Bockmann J, Boeckers TM (2009) Synaptogenesis of hippocampal neurons in primary cell culture. Cell Tissue Res 338:333–341. https://doi.org/10.1007/s00441-009-0881-z
Griffin RJ, Moloney A, Kelliher M et al (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 93:105–117. https://doi.org/10.1111/j.1471-4159.2004.02949.x
Hampel H, Ewers M, Bürger K et al (2009a) Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 70:922–931
Hof PR, Bouras C, Buee L et al (1992) Differential distribution of neurofibrillary tangles in the cerebral-cortex of dementia-pugilistica and Alzheimers-disease cases. Acta Neuropathol 85:23–30
Hooper C, Lovestone S, Sainz-Fuertes R (2008) Alzheimer’s disease, diagnosis and the need for biomarkers. Biomark Insights 3:317–323
Illario M, Monaco S, Cavallo AL et al (2009) Calcium-calmodulin-dependent kinase II (CaMKII) mediates insulin-stimulated proliferation and glucose uptake. Cell Signal 21:786–792. https://doi.org/10.1016/j.cellsig.2009.01.022
Iqbal K, Wang X, Blanchard J et al (2010) Alzheimer’s disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans 38:962–966. https://doi.org/10.1042/BST0380962
Ishiguro K, Omori A, Takamatsu M et al (1992) Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett 148:202–206
Kerr F, Bjedov I, Sofola-Adesakin O (2018) Molecular mechanisms of lithium action: switching the light on multiple targets for dementia using animal models. Front Mol Neurosci 11.https://doi.org/10.3389/fnmol.2018.00297
Klionsky DJ, Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. Science 290:1717–1721
Kremer A, Louis JV, Jaworski T, Van Leuven F (2011) GSK3 and Alzheimer’s disease: facts and fiction…. Front Mol Neurosci 4:17. https://doi.org/10.3389/fnmol.2011.00017
Leroy A, Landrieu I, Huvent I et al (2010) Spectroscopic studies of GSK3β phosphorylation of the neuronal Tau protein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem 285:33435–33444. https://doi.org/10.1074/jbc.M110.149419
Leyhe T, Eschweiler GW, Stransky E et al (2009) Increase of bdnf serum concentration in lithium treated patients with early Alzheimer’s disease. J Alzheimer’s Dis 16:649–656. https://doi.org/10.3233/JAD-2009-1004
Li T, Paudel HK (2006) Glycogen synthase Kinase 3β phosphorylates Alzheimer’s disease-specific Ser 396 of microtubule-associated protein Tau by a sequential mechanism †. Biochemistry 45:3125–3133. https://doi.org/10.1021/bi051634r
Litersky JM, Johnson G V, Jakes R, et al (1996) Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J 316 ( Pt 2:655–60
Lovestone S, Reynolds CH (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78:309–324
Lovestone S, Reynolds CH, Latimer D et al (1994) Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4:1077–1086
Macdonald A, Briggs K, Poppe M et al (2008) A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry 23:704–711. https://doi.org/10.1002/gps.1964
Martins Themoteo R (2021) Lithium prevents telomere shortening in cortical neurons in amyloid-beta induced toxicity. https://doi.org/10.21203/rs.3.rs-260558/v1
Maurer AP, Johnson SA, Hernandez AR, et al (2017) Age-related changes in lateral entorhinal and CA3 neuron allocation predict poor performance on object discrimination. Front Syst Neurosci 11. https://doi.org/10.3389/fnsys.2017.00049
Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6:464–479
McKee AC, Kosik KS, Kennedy MB, Kowall NW (1990) Hippocampal neurons predisposed to neurofibrillary tangle formation are enriched in type II calcium/calmodulin-dependent protein kinase. J Neuropathol Exp Neurol 49:49–63
McNamara CG, Dupret D (2017) Two sources of dopamine for the hippocampus. Trends Neurosci 40:383–384. https://doi.org/10.1016/j.tins.2017.05.005
Mendes CT, Mury FB, De Sá ME et al (2009) Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. Eur Arch Psychiatry Clin Neurosci 259:16–22. https://doi.org/10.1007/s00406-008-0828-5
Morris M, Knudsen GM, Maeda S et al (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18:1183–1189. https://doi.org/10.1038/nn.4067
Nakashima H, Ishihara T, Suguimoto P et al (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110:547–556. https://doi.org/10.1007/s00401-005-1087-4
Nunes MA, Viel TA, Buck HS (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res 10:104–107
Owen R, Gordon-Weeks PR (2003) Inhibition of glycogen synthase kinase 3beta in sensory neurons in culture alters filopodia dynamics and microtubule distribution in growth cones. Mol Cell Neurosci 23:626–637
Peineau S, Bradley C, Taghibiglou C et al (2008) The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153(Suppl):S428–S437. https://doi.org/10.1038/bjp.2008.2
Pérez-Palma E, Bustos BI, Villamán CF, et al (2014) Overrepresentation of glutamate signaling in Alzheimer’s disease: network-based pathway enrichment using meta-analysis of genome-wide association studies. PLoS One 9.https://doi.org/10.1371/journal.pone.0095413
Phiel CJ, Wilson CA, Lee VM-Y, Klein PS (2003) GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature 423:435–439. https://doi.org/10.1038/nature01640
Rocha NKR, Themoteo R, Brentani H, et al (2020) Neuronal–glial interaction in a triple-transgenic mouse model of Alzheimer’s disease: gene ontology and lithium pathways. Front Neurosci 14.https://doi.org/10.3389/fnins.2020.579984
Rockenstein E, Torrance M, Adame A et al (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981–1991. https://doi.org/10.1523/JNEUROSCI.4321-06.2007
Rosso SM, van Herpen E, Pijnenburg YAL et al (2003) Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 60:1209–1213. https://doi.org/10.1001/archneur.60.9.1209
Roux M, Dosseto A (2017) From direct to indirect lithium targets: a comprehensive review of omics data. Metallomics 9:1326–1351. https://doi.org/10.1039/c7mt00203c
Rudrabhatla P, Jaffe H, Pant HC (2011) Direct evidence of phosphorylated neuronal intermediate filament proteins in neurofibrillary tangles (NFTs): phosphoproteomics of Alzheimer’s NFTs. FASEB J 25:3896–3905. https://doi.org/10.1096/fj.11-181297
Ryves WJ, Harwood AJ (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280:720–725. https://doi.org/10.1006/bbrc.2000.4169
Salimi A, Gholamifar E, Naserzadeh P et al (2017) Toxicity of lithium on isolated heart mitochondria and cardiomyocyte: a justification for its cardiotoxic adverse effect. J Biochem Mol Toxicol 31:e21836. https://doi.org/10.1002/jbt.21836
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/emmm.201606210
Shallie PD, Akpan HB, Adefule AK et al (2010) Assessment of lithium ingestion on cognition and some subset of motor skill. J Pharm Bioallied Sci 2:113–117. https://doi.org/10.4103/0975-7406.67016
Sofola O, Kerr F, Rogers I, et al (2012) Correction: Inhibition of GSK-3 ameliorates Aβ pathology in an adult-onset Drosophila model of Alzheimer’s disease. PLoS Genet 8.https://doi.org/10.1371/annotation/baa8a2a9-130b-4959-b6fb-6f786fd02826
Stoothoff WH, Johnson GVW (2005) Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta - Mol Basis Dis 1739:280–297. https://doi.org/10.1016/j.bbadis.2004.06.017
Takahashi M, Tsujioka Y, Yamada T et al (1999) Glycosylation of microtubule-associated protein tau in Alzheimer’s disease brain. Acta Neuropathol 97:635–641. https://doi.org/10.1007/s004010051040
Vianna MR, Barros DM, Silva T et al (2000) Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats. Psychopharmacology 150:77–84
Vieira MNN, Forny-Germano L, Saraiva LM et al (2007) Soluble oligomers from a non-disease related protein mimic Aβ-induced tau hyperphosphorylation and neurodegeneration. J Neurochem 103:736–748. https://doi.org/10.1111/j.1471-4159.2007.04809.x
Wang D, Fu Q, Zhou Y et al (2013) β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J Biol Chem 288:10298–10307. https://doi.org/10.1074/jbc.M112.415141
Wang J-Z, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85:148–175. https://doi.org/10.1016/j.pneurobio.2008.03.002
Watanabe A, Hasegawa M, Suzuki M et al (1993) In vivo phosphorylation sites in fetal and adult rat tau. J Biol Chem 268:25712–25717
Xia L, Nygard SK, Sobczak GG et al (2017) Dorsal-CA1 hippocampal neuronal ensembles encode nicotine-reward contextual associations. Cell Rep 19:2143–2156. https://doi.org/10.1016/j.celrep.2017.05.047
Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Grant No. 466625/2014–6; National Institute for Biomarker Research in Neuropsychiatry (INBION), Grants Nos. 14/50873–3, 2016/01302–9 (FAPESP) and 465412/2014–9 (CNPq); Associação Beneficente Alzira Denise Hertzog da Silva (ABADHS) CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) 88887.463672/2019–00.
Author information
Authors and Affiliations
Contributions
V.J.R.P. conducted experiments on primary neuron culture, protein analysis, and bioinformatics and participated in the writing of the manuscript. O.V.F. participated in the analysis and interpretation of results and writing of the manuscript.
Corresponding author
Ethics declarations
Ethics approval
Animal experiments were approved by the Animal Care and Ethics committee of University of Sao Paulo Medical School, Brazil, under the protocol number 290/11.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
De-Paula, V.J., Forlenza, O.V. Lithium modulates multiple tau kinases with distinct effects in cortical and hippocampal neurons according to concentration ranges. Naunyn-Schmiedeberg's Arch Pharmacol 395, 105–113 (2022). https://doi.org/10.1007/s00210-021-02171-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-021-02171-6